Kairos Pharma, Ltd. announced that its Board authorized a one-for-seven reverse stock split of its common stock, effective September 1, 2026. The company filed a Certificate of Amendment with the Delaware Secretary of State on August 21, 2026, to implement the split, which was previously approved by shareholders at the June 29, 2026 annual meeting. Every seven pre-split shares will combine into one post-split share, with fractional shares rounded up to the nearest whole share. The transaction aims to increase the per-share trading price and maintain compliance with NYSE American listing requirements. Kairos Pharma is a clinical-stage biopharmaceutical company focused on oncology therapeutics.
